Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of postoperative intensity-modulated radiotherapy with concurrent weekly docetaxel in node-positive esophageal cancer
ChiCTR-TNC-10001140Phase 2Completed
- Sponsor
- Affiliated Cancer Hospital of Nanjing Medical University
- Start
- Jan 2011
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel in esophageal cancer, sponsored by Affiliated Cancer Hospital of Nanjing Medical University. Primary endpoints: Overall survival, Liver and renal function and 2 more. Started Jan 2011; status: completed.
02
Drugs
docetaxel
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on ChiCTR-TNC-10001140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TNC-10001140.